GRAIL, Inc. (GRAL) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $50.49. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is GRAL = $88 (+74.3% upside).
Valuation: GRAL trades at a trailing Price-to-Earnings (P/E) of -4.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.43.
Financials: revenue is $147M, +39.9%/yr average growth. Net income is $408M (loss), growing at +38.1%/yr. Net profit margin is -277.5% (negative). Gross margin is -42.5% (+167.1 pp trend).
Balance sheet: total debt is $98M against $2.6B equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 11.97 (strong liquidity). Debt-to-assets is 3.4%. Total assets: $2.9B.
Analyst outlook: 3 / 4 analysts rate GRAL as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 62/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
